RT Journal Article
SR Electronic
T1 Serological assessment of SARS-CoV-2 exposure in northern Sweden by the use of at-home sampling to meet geographical challenges in rural regions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.02.20120477
DO 10.1101/2020.06.02.20120477
A1 Byström, Julia Wigren
A1 Vikström, Linnea
A1 Rosendal, Ebba
A1 Gröning, Remigius
A1 Gwon, Yong-Dae
A1 Nilsson, Emma
A1 Sharma, Atin
A1 Espaillat, Akbar
A1 Hanke, Leo
A1 McInerney, Gerald
A1 Puhar, Andrea
A1 Cava, Felipe
A1 Karlsson Hedestam, Gunilla B
A1 Thunberg, Therese
A1 Monsen, Tor
A1 Elgh, Fredrik
A1 Evander, Magnus
A1 Johansson, Anders
A1 Överby, Anna K
A1 Ahlm, Clas
A1 Normark, Johan
A1 Forsell, Mattias NE
YR 2022
UL http://medrxiv.org/content/early/2022/05/18/2020.06.02.20120477.abstract
AB The current SARS-CoV-2 pandemic has highlighted a need for easy and safe blood sampling in combination with accurate serological methodology. Venipuncture is usually performed by trained staff at health care centers. Long travel distances may introduce a bias of testing towards relatively large communities with close access to health care centers. Rural regions may thus be overlooked. Here, we demonstrate a sensitive method to measure antibodies to the S-protein of SARS-CoV-2. We adapted and optimized this assay for clinical use together with capillary blood sampling to meet the geographical challenges of serosurveillance. Finally, we tested remote at-home capillary blood sampling together with centralized assessment of S-specific IgG in a rural region of northern Scandinavia that encompasses 55,185 sq kilometers. We conclude that serological assessment from capillary blood sampling gives comparable results as analysis of venous blood. Importantly, at-home sampling enabled citizens living in remote rural areas access to centralized and sensitive laboratory antibody tests.Competing Interest StatementJWB, JN and MF are founders and share-holders of Xerum AB.Funding StatementFunding was through grants from Vinnova (2020-03103) to Xerum AB and MF, The Swedish Research Council (2020-06235), Umea University (FS 2.1.6-1233-20) and from the SciLifeLab National COVID-19 Research Program (C19VE:007), financed by the Knut and Alice Wallenberg Foundation to MF; the Swedish Research Council (2021-04665) and Region Vasterbotten (REF) to CA. J.N. is a Wallenberg Center for Molecular Medicine Associated Researcher.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical permission for the study was obtained from the Swedish Ethical review authority (No: 2020-01557) and all research was carried out according to The Code of Ethics of the World Medical Association (Declaration of Helsinki). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available within the article or in supplementary materials